Eli Lilly (LLY +1.23%), one of the biggest drugmakers in the world, continues to face headwinds as two of its top-selling pharmaceuticals are set to lose patent protection this year. However, one of its billion dollar blockbusters from 2012 --the antipsychotic drug Zyprexa -- has already lost patent protection. How has this expiration affected Eli Lilly's total business, and are there any parallels to one of its competitors in this space, beleaguered pharma company AstraZeneca (AZN 0.22%)? Health care analyst Max Macaluso dives into this issue in the following video.
1 Weak Link at This Big Pharma
By Max Macaluso – Feb 14, 2013 at 6:30PM
NYSE: LLY
Eli Lilly
Market Cap
$777B
Today's Change
(1.23%) $10.10
Current Price
$831.14
Price as of October 24, 2025 at 10:14 AM ET
1 drug that Eli Lilly has already lost exclusivity for.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo